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Abstract. We report outcomes and 12-month survival for the first cohort of patients to undergo multidrug-resistant
tuberculosis (MDR-TB) treatment after the earthquake in Haiti. From March 3, 2010 to March 28, 2013, 110 patients
initiated treatment of laboratory-confirmed MDR-TB at the Groupe Haı¨tien d’Etude du Sarcome de Kaposi et des
Infections Opportunistes (GHESKIO) Center in Port-au-Prince, Haiti. Twenty-seven patients (25%) were human
immunodeficiency virus (HIV)-positive. As of October 31, 2013, 95 (86%) patients were either cured or alive on
treatment, 4 (4%) patients defaulted, and 11 (10%) patients died. Culture conversion occurred by 30 days in 14 (13%)
patients, 60 days in 49 (45%) patients, and 90 days in 81 (74%) patients. The probabilities of survival to 12 months
were 96% (95% confidence interval [95% CI] = 89–99) and 85% (95% CI = 64–94) for HIV-negative and -positive
patients, respectively. Despite adverse conditions, outcomes for patients with MDR-TB are highly encouraging. Major
efforts are underway to scale up community directly observed therapy and expand care to other regions of Haiti.
INTRODUCTION
Multidrug-resistant tuberculosis (MDR-TB), defined as tuber-
culosis (TB) resistant to at least isoniazid and rifampin (two
of the most effective drugs against TB), represents a major
public health problem worldwide. According to the World
Health Organization (WHO), an estimated 450,000 people
developed MDR-TB and 170,000 people died of MDR-TB in
the world in 2013.1 Treatment of MDR-TB is costly, requires
18–24 months before patients can be deemed cured of the
disease, results in lower cure rates than the treatment of drug-
susceptible TB, and can lead to severe adverse reactions.2
Human immunodeficiency virus (HIV) -positive patients with
MDR-TB face higher mortality than HIV-negative patients
and tend to experience more adverse events.3,4
At an estimated annual incidence of 213 cases per 100,000
people, Mycobacterium tuberculosis infection in Haiti is
among the highest in the world.5 No national survey of
MDR-TB prevalence has been conducted yet in Haiti, but a
study conducted in 2008 in 1,000 patients in the West
Department, where roughly one-half of all TB cases occur,
estimated the prevalence of MDR-TB among newly diag-
nosed cases of TB at 2.9%.6 The WHO estimates national
MDR-TB prevalence at 2.2% among new cases or 14% in
those receiving category II retreatment regimens.5 HIV-
positive patients in Haiti have also been found to have a
higher prevalence of MDR-TB.7
In the aftermath of the earthquake of January 12, 2010,
most health facilities in Port-au-Prince and its surroundings
were damaged or destroyed, and over 1.5 million people
settled in makeshift camps, tent cities, and slums.8 Before
the earthquake, the only inpatient facility for the treatment
of MDR-TB in the West Department was the Ministry of
Health–Groupe Haı¨tien d’Etude du Sarcome de Kaposi et des
Infections Opportunistes (GHESKIO) Hospital in Leogane.
The facility was completely destroyed in the earthquake.
GHESKIO responded by setting up a field hospital for the
management of patients with MDR-TB in Port-au-Prince.
Patients were housed separately in isolation tents.
The main objective of this study was to describe treatment
outcomes and factors associated with culture conversion and
12-month survival for the first cohort of patients to receive
MDR-TB treatment in the aftermath of the earthquake in
Port-au-Prince, Haiti. As mycobacterial culture and rapid
molecular diagnostics for TB are expanded in Haiti, it is
expected that many more MDR-TB patients will be diag-
nosed and need to be managed. Information about models
of care and associated patient outcomes is essential to guide
future therapeutic approaches for MDR-TB patients.
METHODS
Study setting and patient population. The study was con-
ducted at GHESKIO, a non-governmental organization based
in Port-au-Prince that has provided care to individuals with
TB, HIV/acquired immunodeficiency syndrome (AIDS), and
sexually transmitted infections for over three decades.
GHESKIO is one of two non-governmental organizations
in Haiti that provides treatment of patients with MDR-TB;
Partners in Health/Zanmi Lasante runs the other program
in central Haiti. All patients with microbiologic evidence of
resistance to at least isoniazid and rifampin who initiated
MDR-TB treatment at GHESKIO from March 3, 2010 to
March 28, 2013 were included in this study. Test results
included positive sputum smear microscopy and/or Xpert MTB/
RIF (Cepheid, Sunnyvale, CA) results showing M. tuberculosis
resistant to rifampin or sputum cultures positive forM. tuberculosis
and either GenoType MTBDRplus assay (v1.0, Hain
Lifescience, Nehren, Baden-Wu¨rttemberg, Germany) or con-
ventional drug susceptibility test (DST). On being informed of
the diagnosis of MDR-TB, patients received counseling,
expressed verbal understanding of their diagnosis, and signed
a consent form to undertake care. Patients were asked to
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designate a family member or friend to accompany them for
support during the course of treatment.
Laboratory procedures. Mycobacterial cultures were per-
formed at GHESKIO’s Rodolphe Me´rieux Biosafety Level 3
Laboratory in Port-au-Prince, Haiti. Sputum specimens col-
lected from patients suspected of having TB were stained by
the Ziehl–Neelsen method and examined by microscopy for the
presence of acid-fast bacilli. The GeneXpert M. tuberculosis
and rifampin resistance (Xpert MTB/RIF) detection assay,
which became available in May of 2011, was performed con-
currently on the sputum specimens. After decontamination
with N-acetyl-L-cysteine-sodium hydroxide, specimens were
cultured, and first-line DST was performed using the
BACTEC MGIT 960 System (Becton-Dickinson, Sparks,
MD). The GenoType MTBDRplus assay (v1.0, Hain Life
Sciences, Germany) was done for all positive cultures. When
first-line DST results confirmed resistance to at least isoniazid
and rifampin, second-line DST was performed by the propor-
tion method with 7H10 agar plates. The following drugs were
included in the second-line DST at standard concentrations9:
ofloxacin, kanamycin, amikacin, capreomycin, ethionamide,
cycloserine, and para-aminosalicylic acid (PAS).
Strict internal and external quality assurance standards
were established and followed for all laboratory procedures.
GHESKIO’s Rodolphe Me´rieux Laboratory participates
in several external quality assurance (EQA) programs. The
results in EQA programs for mycobacteriology (College of
American Pathologists), Xpert MTB/RIF (two programs:
Centers for Disease Control and Prevention [CDC] and
Division of Acquired Immunodeficiency Syndrome [DAIDS]
Clinical Trials Group), and line probe assays (WHO Stop TB
Department) have been 100% successful since 2008.
MDR-TB treatment protocol—drug regimens and follow-up
of patients. Patients with MDR-TB were initiated on an
empiric regimen that included at least four drugs to which
the M. tuberculosis isolate was likely to be susceptible.2,10
The initial empiric regimen consisted of a later-generation
quinolone (levofloxacin or moxifloxacin), a parenteral agent
(kanamycin or capreomycin), cycloserine, pyrazinamide, and
ethionamide. High-dose isoniazid was added, because 15–20%
of patients have isolates resistant to ethionamide.11 Because of
funding constraints and the prohibitive cost of PAS, a decision
was reached in May of 2011 to limit the use of PAS to HIV-
positive patients, patients with advanced pulmonary disease,
and patients with intolerance to cycloserine in accordance with
Haiti National Tuberculosis Program guidelines. Capreomycin
and moxifloxacin were used in HIV-positive patients, patients
with diabetes, and patients with advanced pulmonary disease.
Kanamycin and capreomycin were dosed one time per day for
6 days per week. Cycloserine and ethionamide were dosed two
times per day.
Drug regimens were adjusted on an individual basis on the
availability of the second-line DST results. High-dose isoni-
azid was discontinued if the isolate displayed sensitivity to
ethionamide. PAS was used in patients whose isolates were
resistant to ethionamide. The parenteral agent was discon-
tinued after six consecutive negative cultures.
Patients were hospitalized in individual tents (Figure 1)
during the initial phase of treatment for 3–8 months to ensure
optimal treatment response, monitor closely for signs of
toxicity, and reinforce adherence. Adverse drug effects of
grade 3 or higher were noted. HIV-positive patients who
had not yet received antiretroviral therapy (ART) were
placed on a regimen consisting of ritonavir-boosted lopinavir
and two nucleoside reverse transcriptase inhibitors within
1–2 weeks of starting MDR-TB treatment, regardless of
their CD4 T-cell count.12
On discharge, patients received domiciliary directly-observed
therapy (DOT) two times per day from nurse auxiliaires
while on parenteral drug therapy and a community health
worker after completion of the parenteral drug. Patients had
weekly follow-up visits with the medical team for the first 6
months of ambulatory care, then visits every other week for
the second 6 months, and visits monthly for the second year
of treatment. Sputum specimens were collected for acid-fast
smear microscopy and M. tuberculosis culture monthly over
the course of treatment. Because audiograms were not rou-
tinely available, hearing impairment and vestibular toxicity
were assessed clinically. The cause of death was determined
after a thorough review of patients’ records by the medical
team to reach a decision as to the most probable cause of
death. Lung resection surgery was not available.
Patients were offered psychosocial support through indi-
vidual counseling sessions and monthly group support meet-
ings. Family members and friends were strongly encouraged
to attend the monthly meetings. Dry food rations were offered
to patients in an attempt to obtain a better response to treat-
ment and promote adherence. Incentives, such as mobile
phones, phone recharge cards, transportation fees, and an
end-of-treatment prize and certificate, were given to patients
to reinforce adherence and increase retention.
Outpatient DOT provider’s activities were monitored
daily by mobile phones equipped with global positioning
system (GPS). Nurse auxiliaires and fieldworkers recorded
patients’ symptoms, vital signs, and weight and took pic-
tures of the patients swallowing the medications. GPS coor-
dinates were recorded automatically. Files were downloaded
and examined daily to verify DOT. Patients who missed
doses and/or visits were called promptly to be reminded
and visited by the nurse. Staff meetings were held with
patients who missed doses and/or visits and their designated
family member or friend to help identify specific barriers to
adherence and offer ways of reinforcing adherence.
Data collection and analysis. Demographic variables, clini-
cal characteristics, and laboratory and radiographic results were
Figure 1. The GHESKIO MDR-TB Field Hospital established
after the earthquake of January 12, 2010.
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collected through review of medical records and laboratory
information and entered into a Microsoft Excel spreadsheet
(Microsoft, Redmond, WA). The STATA 12.1 software pack-
age (College Station, TX) was used for data analysis.
Patient characteristics and outcomes were compared for
HIV-negative and HIV-positive patients. The two primary
outcome measures in our study were time to sputum culture
conversion and survival. MDR-TB treatment outcomes were
based on WHO definitions and included the following cate-
gories: cure, completion, default, failure, and death.13 Favor-
able outcomes included cured, treatment completion, and
alive on treatment; adverse outcomes included death, default,
and failure.
Categorical variables were summarized as proportions
and frequencies, and confidence intervals (CIs) were calcu-
lated at the 95% level. Univariate analyses were performed
to determine associations between baseline characteristics
and outcomes. Kaplan–Meier analysis was used to assess
survival probabilities; differences between the two survival
curves were determined by the log-rank test. Patients were
censored at the time of analysis (October 31, 2013). Cox
proportional hazards regression analysis was used to esti-
mate the hazard ratios with 95% CIs. Predictors in the
model for death were selected based on prior research expe-
rience and factors described in the literature. Odd ratios
and P values were two-tailed; P values of 0.05 or lower
were considered statistically significant.
This study was approved by the GHESKIO and Weill
Cornell Medical College Institutional Review Boards.
RESULTS
Baseline demographic and clinical characteristics of the
patient population. The median time from treatment initia-
tion to data analysis was 22.5 months (interquartile range
[IQR] = 11.5–31.0 months). Table 1 summarizes the demo-
graphic and clinical characteristics of 110 patients who ini-
tiated MDR-TB treatment in the GHESKIO MDR-TB
program from March 3, 2010 to March 28, 2013. Sixty (55%)
patients were female. The median age was 28 years (IQR =
23–37 years). Eighty-six (79%) patients lived on less than
$1 per day; 74 (67%) patients either lived or had access to
a residence in the Port-au-Prince metropolitan area.
Ninety-eight (89%) patients had received first-line anti-TB
drugs before initiating MDR-TB treatment, and no patients
had prior exposure to second-line drugs. The median weight
was 50.2 kg (IQR = 45.0–55.0 kg) for men and 45.8 kg
(IQR = 40.0–52.0 kg) for women. Eighty-five (79%) patients
had bilateral lung involvement on baseline chest radiographs.
Lung parenchymal tissue damage in the form of cavitary dis-
ease, fibrosis, and cysts was seen in 77 (72%) patients. The
median hemoglobin level at baseline was 11.0 g/dL (IQR =
9.5–12.7 g/dL). The median delay in initiating treatment
was 42.5 days in patients with Xpert MTB/RIF results and
48.5 days in patients without results.
Twenty-seven (25%) patients were HIV-positive, with a
median CD4 T-cell count of 329 (IQR = 53–608). There
were no significant differences in baseline characteristics
between HIV-negative and HIV-positive patients, except
for the level of education and median hemoglobin level
(Table 1).
Mycobacterial culture and DST results. Mycobacterial cul-
ture and DST results were positive for M. tuberculosis in
107 patients. Two patients had Xpert MTB/RIF results indi-
cating rifampin-resistant M. tuberculosis, but the cultures
did not grow. One patient had a mixture of M. tuberculosis
and M. avium complex, but the M. tuberculosis isolate
showed resistance to isoniazid and rifampin by the GenoType
MTBDRplus assay (v.1.0).
DST results for 107 patients are summarized in Table 2.
Patients were resistant to a mean of 3.8 (SD = 1.4) drugs;
55 (51%) patients had isolates resistant to streptomycin,
83 (78%) patients had isolates resistant to ethambutol, and
54 (51%) patients had isolates resistant to pyrazinamide.
One hundred (93%) patients had isolates with the S315T
katG mutation associated with high-level resistance to isonia-
zid. As for resistance to second-line drugs, 17 (16%) patients
had isolates resistant to ethionamide, and 1 (1%) patient had
resistance to ofloxacin. No isolates were found to be resis-
tant to kanamycin, capreomycin, cycloserine, or PAS. No
cases of extremely drug-resistant TB were found.
MDR-TB drug regimens and ART. The median time
from diagnosis to initiation of MDR-TB treatment was 46 days
(IQR = 21–77 days) for the entire population, 63 days (IQR =
37–90 days) for HIV-negative patients, and 50 days (IQR =
41–72 days) for HIV-positive patients. Table 3 summarizes the
empiric MDR-TB drug regimens initiated for 110 patients in
the study according to HIV status. Moxifloxacin, capreomycin,
and PAS were more frequently included in the empiric regi-
mens for HIV-positive patients.
Table 1
Baseline characteristics of 110 MDR-TB patients according to HIV status
Characteristic Entire population (N = 110) HIV-negative (N = 83) HIV-positive (N = 27) P value
Age (years), median (IQR) 28 (23–37) 28 (22–36) 30 (26–39) 0.268
Female sex, no. (%) 60 (54.6) 45 (54.2) 15 (55.6) 0.903
Lives on < $1/day, no. (%) 86 (78.2) 67 (80.7) 19 (70.4) 0.258
Education at primary level or lower, no. (%) 49 (44.6) 32 (38.6) 17 (63.0) 0.027
Lives in Port-au-Prince area, no. (%) 74 (67.3) 55 (66.3) 19 (70.4) 0.693
Initial weight (kg), median (IQR) 48.0 (41.8–53.6) 48.3 (41.0–54.0) 46.0 (44.0–50.4) 0.318
Previous TB treatment, no. (%) 95 (88.8) 69 (86.3) 26 (96.3) 0.153
Time from diagnosis to start of treatment, median days (IQR) 46 (20.8–77.3) 48 (17–82) 42 (23–66) 0.182
Radiographic findings (N = 99)
Bilateral lung disease 85 (79.4) 63 (75.9) 22 (95.7) 0.084
Chronic changes (fibrosis, cysts, cavities, or bullae) 77 (72.0) 60 (72.3) 17 (72.8) 0.889
Hemoglobin, median (IQR) 11.0 (9.5–12.7) 11.4 (9.7–12.9) 9.7 (6.6–11.1) 0.011
Hemoptysis 22 (20.0) 21 (25.3) 1 (3.7) 0.015
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All 27 HIV-positive patients received ART within 2 weeks
of starting MDR-TB treatment. Twelve (44%) patients
had received ART before staring treatment of MDR-TB;
15 (56%) patients had a diagnosis of HIV concomitant with
the initiation of MDR-TB treatment and had never received
ART before.
Adverse events in patients receiving MDR-TB treatment.
Adverse drug-related events were noted in 61 (56%) of
110 patients. Table 4 shows the adverse drug reactions found
in patients receiving treatment. Among patients with the
most frequently noted reactions, the following reactions
were found: peripheral neuropathy (14%), arthralgia (13%),
neuropsychiatric disturbance (psychosis, anxiety, and sei-
zure) (16%), gastrointestinal distress (11%), and hearing
impairment (11%). Two patients experienced permanent
hearing loss and had to be fitted for hearing aids. Dis-
continuation of cycloserine occurred in six (5%) patients
with psychosis, which was the most frequent cause of drug
change for adverse drug-related events. There were no cases of
drug-induced hepatitis. Overall, the occurrence of any adverse
drug event was not significantly higher in HIV-positive
patients than HIV-negative patients (12 [44%] versus 49 [59%]
patients, P = 0.185). Depression was significantly more
common in HIV-positive patients than HIV-negative patients
(5 [19%] versus 2 [2%] patients, P = 0.003).
The course of treatment was complicated by a requirement
for oxygen supplementation and hemoptysis in 18 (16%) and
22 (20%) patients, respectively.
Sputum culture conversion. Sputum culture conversion was
achieved by 30 days in 14 (13%) patients, 60 days in 49 (45%)
patients, and 90 days in 81 (74%) patients; 14 (52%) HIV-
positive patients had culture conversion by 60 days com-
pared with 35 (42%) HIV-negative patients (P = 0.379).
Factors associated with achieving culture conversion by
60 days were having an isolate resistant to only isoniazid
and rifampin (odds ratio [OR] = 3.5, 95% CI = 1.3–10.4,
P = 0.011) and having a diagnosis of MDR-TB by the Xpert
MTB/RIF assay (OR = 3.3, 95% CI = 1.5–7.2, P = 0.003).
Patients with isolates resistant to pyrazinamide were less
likely to achieve culture conversion by 60 days (OR = 0.4,
95% CI = 0.2–0.9, P = 0.021).
MDR-TB treatment outcomes. The median time spent
on treatment was 17.8 months for the cohort (IQR =
10.3–24.0 months). Overall, 95 (86%) patients were either
cured or alive on treatment over the course of the analysis,
with 43 (39%) patients cured and 52 (47%) patients alive
on treatment at the time of the analysis (Table 5). Among
HIV-negative patients, 74 (89%) patients were either cured
or alive on treatment, with 34 (41%) patients cured and
40 (48%) patients alive on treatment, whereas among HIV-
positive patients, 21 (78%) patients were cured and alive
on treatment, with 9 (33%) patients cured and 12 (44%)
patients alive on treatment. Four patients (4%) defaulted
on treatment: two patients at 17 months, one patient at
7 months, and one patient at 5 months of treatment.
Eleven (10%) patients died. The causes of death were
related to MDR-TB and its complications in seven patients
(respiratory failure in five patients and pneumothorax in
two patients) and unrelated to TB in four patients (one patient
died of advanced HIV/AIDS, one patient died of of cholera
and HIV/AIDS, one patient died of severe anemia, and
one patient committed suicide). Deaths occurred within a
median of 3.4 months (IQR = 1.4–16.7 months) after treat-
ment was initiated; 5 (46%) of 11 deaths occurred among
HIV-positive patients. No significant associations were found
between chest radiograph findings and outcome.
According to Kaplan–Meier survival analysis (Figure 2),
the probability of survival to 12 months after initiating treat-
ment of MDR-TB was estimated at 96% (95% CI = 89–99)
for HIV-negative patients and 85% (95% CI = 64–94) for
HIV-positive patients. There was a trend toward greater
survival for HIV-negative patients than HIV-positive patients
Table 3
Second-line MDR-TB drugs used in the empiric regimens for 110
patients in the study
Entire population
(N = 110)
HIV-negative
(N = 83)
HIV-positive
(N = 27) P value
Kanamycin 96 (87.3) 78 (94.0) 18 (66.7) < 0.0005
Capreomycin 14 (12.7) 5 (6.0) 9 (33.3) < 0.0005
Levofloxacin 86 (78.2) 73 (88.0) 13 (48.2) < 0.0005
Moxifloxacin 14 (12.7) 10 (12.1) 14 (51.9) < 0.0005
Cycloserine 108 (98.2) 81 (97.6) 27 (100.0) 0.416
PAS* 64 (58.2) 39 (47.0) 25 (92.6) < 0.0005
Pyrazinamide 106 (96.4) 82 (98.8) 24 (88.9) 0.017
High-dose
isoniazid
44 (40.0) 42 (50.6) 2 (7.4) < 0.0005
Amoxicillin/
clavulanate
2 (0.2) 2 (2.4) 0 (0) 0.416
*As of May of 2011, PAS was used only in HIV-positive patients, patients with advanced
pulmonary disease, and patients with intolerance to cycloserine per the Haiti National
Tuberculosis guidelines.
Table 4
Adverse drug reactions in 110 MDR-TB patients in the study
Entire population
(N = 110)
HIV-negative
(N = 83)
HIV-positive
(N = 27) P value
Gastrointestinal
distress
12 (10.9) 9 (10.8) 3 (11.1) 0.969
Neuropsychiatric
disturbance
18 (16.4) 11 (13.3) 7 (25.9) 0.122
Ototoxicity 12 (10.9) 11 (13.3) 1 (3.7) 0.167
Nephrotoxicity 3 (2.7) 1 (1.2) 2 (7.4) 0.086
Hypothyroidism 5 (4.5) 5 (6.0) 0 (0) 0.192
Arthralgia 14 (12.7) 12 (14.5) 2 (7.4) 0.34
Gynecomastia 4 (3.6) 4 (4.8) 0 (0) 0.245
Peripheral neuropathy 15 (13.6) 13 (15.7) 2 (7.4) 0.278
Dermatologic 5 (4.6) 5 (6.0) 0 (0) 0.192
Table 2
Drug resistance profiles of M. tuberculosis isolates cultured from
sputum specimens of 107 patients with culture and drug suscep-
tibility results
Resistance
Entire population
(N = 107)
HIV-negative
(N = 83)
HIV-positive
(N = 24) P value
Number of drugs to
which isolate was
resistant, mean
3.84 3.84 3.81 0.925
Pyrazinamide
resistance, no. (%)
54 (50.5) 43 (51.8) 11 (45.8) 0.605
Ethambutol
resistance, no. (%)
83 (77.6) 61 (73.5) 22 (91.7) 0.060
Streptomycin
resistance, no. (%)
55 (51.4) 39 (47.0) 16 (66.7) 0.089
Ofloxacin
resistance, no. (%)
1 (0.9) 1 (1.2) 0 (0) 0.567
Ethionamide
resistance, no. (%)
17 (15.9) 11 (13.3) 6 (25.0) 0.168
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(P = 0.055 by the log-rank test). The unadjusted hazard ratio
(HR) for the risk of death for HIV-positive patients com-
pared with that for HIV-negative patients was 3.1 (95% CI =
0.9–10.1, P = 0.068). For HIV-positive patients, a CD4 T-cell
count < 100 was a predictor of death (unadjusted HR = 9.8,
95% CI = 2.8–33.9, P < 0.0005). Predictors of mortality
(Table 6) were occurrence of adverse neuropsychiatric
events in the first 1 month of treatment, hemoglobin level
of 9.5 g/dL or lower at baseline, and failure to achieve
sputum culture conversion by 60 days. There was no asso-
ciation found between either weight loss within the first
6 months or pyrazinamide resistance and mortality.
DISCUSSION
Outcomes for patients with MDR-TB have been out-
standing for the first 110 patients to receive treatment after
the devastating earthquake in Port-au-Prince, Haiti; 86%
of patients are cured or remain on treatment. Although
patients are hospitalized in tents during inpatient therapy,
these outcomes rival the most successful treatment cohorts
from other more favorable settings worldwide.
Most patients (72%) in our study had advanced parenchy-
mal tissue destruction, involving both lungs in 79% of
patients. Some of these patients posed major challenges for
medical management in the setting of a field hospital under
tents: 18% of patients had hemoptysis, and 20% of patients
required supplemental oxygen. Factors that contributed to
the success of treatment in our cohort included the low mean
resistance to first-line drugs (19% of the patients had iso-
lates resistant to isoniazid and rifampin only), the aggres-
sive empiric drug regimens used,14,15 and the dedication of
the staff.
HIV-positive patients tended to have a lower survival
than HIV-negative patients, which has been reported
elsewhere,16–18 but they were no less likely to be lost to
follow-up. Also, they did not have delays in culture conver-
sion compared with HIV-negative patients.
The immediate availability of ART and the relatively
preserved immunologic status of the patients also contrib-
uted to the relatively high survival of HIV-positive patients
over the course of the study.
Our results are highly encouraging given the low treatment
success rates that have been reported from other treatment
cohorts.19–21 In a recent individual patient data meta-analysis
of 9,153 patients, the pooled treatment success was only 54%
(95% CI = 53–55%).22 In that study, treatment success was
associated with use of later-generation quinolones, ethion-
amide, or prothionamide, use of four or more likely effective
drugs in the initial intensive phase, and use of three or more
likely effective drugs in the continuation phase. In addition,
the greatest odds of success were seen in patients who had
7.0–8.5 months for the intensive phase and a total length of
treatment of 24.6–27.5 months. Because of the low rate of
second-line drug resistance and our long duration of inject-
able therapy, our treatment cohort received these favorable
treatment conditions.
Anemia, defined as hemoglobin in the lowest quartile for
the entire MDR-TB cohort (£ 9.5 g/dL), was a predictor for
mortality in our study, indicating that undernutrition may
be a major factor for death in these poor patients. Indeed,
undernutrition is a risk factor for TB and can adversely
impact response to TB treatment.23,24 Nearly 80% of
patients in our cohort lived on less than $1 a day, and
many required food supplements over the course of treat-
ment. According to the International Food Policy Research
Institute,25 Haiti’s global hunger index of 23.3 is still consid-
ered disquietingly high, indicating that “more than 44 percent
of Haiti’s population is undernourished and more than half
of the households live on less than one dollar a day.” Suc-
cessful scale-up of MDR-TB care in Haiti will require the
Table 5
MDR-TB treatment outcome for 110 patients in the study
Entire population (N = 110) HIV-negative (N = 83) HIV-positive (N = 27) P value
MDRTB treatment outcome 0.398
Cured 43 (39.1) 34 (41.0) 9 (33.3)
Alive on treatment 52 (47.3) 40 (48.2) 12 (44.4)
Died 11 (10.0) 6 (7.2) 5 (18.5)
Defaulted 4 (3.6) 3 (3.6) 1 (3.7)
Figure 2. Kaplan–Meier estimates of the probability of survival
after starting treatment of MDR-TB in HIV-negative and HIV-
positive patients.
Table 6
Predictors of death in 110 patients receiving MDR-TB treatment
Predictor
Adjusted HR*
(95% CI)
Unadjusted HR
(95% CI) P value
Occurrence of adverse
neuropsychiatric event
in the first 1 month
of treatment
5.0 (2.3–95.3) 4.8 (1.3–16.8)
P = 0.015
0.004
Hemoglobin in lowest quartile
(£ 9.5 g/dL)
4.8 (1.3–17.9) 5.5 (1.6–18.7)
P = 0.007
0.018
Culture conversion
after 60 days
10.1 (1.1–90.0) 6.9 (0.9–54.3)
P = 0.067
0.039
*HRs have been adjusted for age, sex, education level, economic status, baseline weight,
and the other variables listed.
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support of the National Tuberculosis Program and its part-
ners to implement a complete care package, including robust
psychosocial support for patients, nutritional support through-
out the course of treatment, and development of poverty-
reducing programs, such as microcredit, skills workshops, and
adult education.
Over one-half of the patients in our cohort reported
at least one adverse drug effect. Among the most severe
adverse drug-related events were neuropsychiatric disturbance,
hearing impairment, and renal toxicity. The occurrence of
neuropsychiatric events in our study was higher than has been
reported elsewhere.26–28 There was one suicide in our cohort
in a 27-year-old male patient who had been receiving treat-
ment for 38 days. This event underscores the need for effec-
tive tools to screen for psychiatric illness and early signs of
adverse neuropsychiatric complications to avert these pre-
ventable deaths. There are few psychiatrists in Haiti and
other resource-poor settings, and therefore, it is essential to
train medical staff to recognize early warning signs of neuro-
psychiatric illness to effectively prevent its devastating con-
sequences in this population. Because cycloserine levels are not
measured because of financial and logistical challenges, it is
possible that high cycloserine levels may pre-dispose patients to
psychiatric complications. The use of high-dose isoniazid in the
empiric regimen may also contribute to psychiatric side effects.
Most patients (74%) in the cohort reached culture conver-
sion by 90 days, similar to reported percentages for other
cohorts.29–31 Interestingly, patients with isolates resistant to
pyrazinamide were found to be less likely to achieve culture
conversion by 60 days. The introduction of the Xpert MTB/
RIF assay allowed for rapid diagnosis of MDR-TB treatment,
particularly in patients with no overt signs of failure. How-
ever, even when molecular diagnostics allowed for prompt
diagnosis, it still took a relatively long time to mobilize
resources and convince patients and family members of the
necessity of initiating treatment immediately. Patients who
were relatively healthy at the time of diagnosis tended to
refuse hospitalization on the grounds that they had other
responsibilities to attend to and could not afford to be hos-
pitalized. Extending MDR-TB education and management
to the community will be important to enroll more patients
in care more expeditiously. Despite these impediments,
patients who had a diagnosis of MDR-TB by the Xpert
MTB/RIF assay took a shorter amount of time to achieve
culture conversion.32,33 Indeed, because we implemented a
systematic approach of initiating MDR-TB treatment based
solely on the Xpert MTB/RIF result, more patients have
been initiated on treatment sooner, and the time to culture
conversion has been reduced to 45 days. All three major
predictors of mortality (adverse neuropsychiatric events in
the first 1 month of treatment, low hemoglobin level, and
failure to achieve sputum conversion by 60 days) can be known
within the first 2 months and can help identify patients at
greatest risk of death so that they can receive more attention
to try to reverse their projected bad outcomes.
Our study has some limitations. First, we cannot entirely
exclude the potential for selection bias, because many patients
were referred to our center for evaluation of failure of first-
line drugs. It could be that patients who were seriously ill
could not be referred for evaluation and treatment. Second,
adverse events could have been underestimated, because
patients could have underreported their symptoms; also, spo-
radic lack of funds precluded systematic laboratory investi-
gation of patients’ symptoms.
In conclusion, despite these limitations, our study shows
that outstanding outcomes can be achieved in MDR-TB
treatment, even in the aftermath of a devastating natural
catastrophe. As treatment is expanded countrywide, it will
be crucial to train health professionals and community health
workers and strengthen social support networks for patients
to ensure continued success.
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